The FDA has approved the first biosimilar version of the interleukin-6 (IL-6) blocker tocilizumab, to be marketed as Tofidence and with indications for rheumatoid arthritis (RA), systemic juvenile ...
On March 7, Fresenius Kabi announced that the FDA has approved its tocilizumab biosimilar, TYENNE (tocilizumab-aazg) for inflammatory and immune diseases indications including rheumatoid arthritis, ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
Roche believes it has exited phase 3 with data to support talks with regulatory agencies, but the mixed results raise ...
Dr. Reddy’s Laboratories RDY announced that the phase I study for its biosimilar candidate of Roche’s RHHBY drug Actemra (tocilizumab), DRL_TC, met its primary and secondary endpoints. The phase I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback